Skip to main content

Amivantamab/Lazertinib is a Potential Chemo-Free Option in EGFR-Mutated NSCLC

*July 2023*

Benjamin Besse, MD, PhD, professor of medical oncology at Université Paris-Saclay and Head of Clinical Research at Gustave Roussy, discusses the biomarker analysis of cohort D of the phase 1/1b CHRYSALIS-2 (NCT04077463) study.

In the trial, the efficacy of amivantamab (Rybrevant) and lazertinib (Leclaza) is being evaluated for the treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC) whose disease progressed on or after treatment with osimertinib (Tagrisso).

According to Besse, updated findings from the treatment-naïve cohort from the phase 1/1b CHRYSALIS trial demonstrated activity, including an overall response rate of 61% and a median progression-free survival of 12.2 months compared with 14% and 4.2 months for patients with NSCLC with low MET expression. Watch the video or read the transcript here.